It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.
Target Classes
Driving discovery across diverse target classes with integrated expertise and advanced, decision-ready solutions.
From ion channels and GPCRs to transporters, kinases, helicases, and more, co-located teams deliver tailored workflows and collaborate to accelerate your program from target validation to candidate selection.
Access one of the industry’s most comprehensive portfolios of target class solutions across ion channels, GPCRs, transporters, kinases, helicases and more.
Our integrated drug discovery teams bring advanced assay technologies together with structural biology and medicinal chemistry to deliver rapid, reliable data at every stage.
From custom cell-based tools and high-throughput screening to integrated chemistry and DMPK support, we design tailored workflows that accelerate hit identification and optimize leads as part of a seamless DMTA cycle. Every assay is developed and validated in-house using innovative technologies so your decisions are grounded in reproducible data you can trust.
Whether your program needs bespoke assay development, scalable screening strategies, or integrated cascades for complex targets, our teams partner closely with you to provide technical expertise, personalized guidance, and robust data that helps you move forward with clarity.
Target class areas
We have extensive expertise in generating and validating stable cell lines expressing membrane proteins, cytosolic proteins, and more, applying a comprehensive suite of advanced technologies so downstream needs are met with precision.
Ion Channels
End-to-end screening, using 150+ validated recombinant cell lines alongside state-of-the-art fluorescence and electrophysiology platforms, delivering tailored and reliable data with seamless support to accelerate leads quickly.
Deep GPCR and cell-signalling expertise including custom assay development, transient or stable cell systems, high-throughput screening and functional readouts, with structural biology support to accelerate hit-to-lead programs.
Custom transporter discovery platform delivering tailored cell-based assays for screening, profiling, and lead optimization, supported by advanced electrophysiology technologies and validated tools to generate robust, reproducible data and accelerate therapeutic programs.
